DATE CONFERENCE TITLE AUTHORS
May 2020 American Association of Immunologists Annual Meeting PT101: A Treg selective agonist IL-2 mutein therapy for autoimmunity Nathan Higginson-Scott, Kevin L. Otipoby and Jo Viney
Mar 2020 Keystone T Cell Memory Discovery and Characterization of Tissue-Tethered PD-1 Agonist Antibodies Bridget Larkin, Lindsay J. Edwards, Daniel C. Rios, Salvatore Alioto, Timothy Kiprono, Nathan Higginson-Scott, Joanne L. Viney, Kevin L. Otipoby
Feb 2020 JDRF nPOD (Network for Pancreatic Organ Donors with Diabetes) Annual Meeting Bifunctional Antibody Therapy for the treatment of Type 1 Diabetes Daniel Rios
Dec 2019 Antibody Engineering and Therapeutics; San Diego, CA Development of PD-1 agonist bispecific antibodies for tissue targeted immunomodulation Salvatore L. Alioto, Lindsay J. Edwards, Bridget M. Larkin, Angela Boisvert, Jyothsna Visweswaraiah, Joanne L. Viney, Kevin L. Optipoby, Nathan Higginson-Scott
Nov 2019 JDRF New England Awards Ceremony; Boston, MA Tissue-Specific Immunomodulation as a Novel Treatment for T1D Daniel Rios
Nov 2019 The Promise of Interleukin-2 Therapy; Paris, France PT101, A Highly Selective IL-2 Mutein for AutoimmunityICMI Kevin L. Otipoby, Nathan Higginson-Scott, Jo Viney
Sept 2019 World Bispecific Summit; Waltham, MA De-risking Bispecific Developability with Early Screens in Bispecific Format Nathan Higginson-Scott
Sept 2019 World Bispecific Summit; Waltham, MA Developing targeted IL-2 mutein bispecific antibodies for gut localized immune modulation Jyothsna Viswesvaraiah, Erik Sampson, Bridget Larkin, Tim Kiprono, Lindsay Edwards, Sal Alioto, Angela Boisvert, Jo Viney, Kevin Otipoby, Nathan Higginson-Scott
July 2019 Presentation at St. Vincent's Institute of Medical Research; Fitzroy, Australia Enforcing Checkpoint Regulation: Tissue Specific PD-1 Agonism as a Novel T1D Therapeutic Approach Developing targeted IL-2 mutein Daniel Rios
July 2019 International Congress of Mucosal Immunology; Brisbane. Australia Selective Expansion of Regulatory T cells by IL-2 Muteins as a Potential Treatment for IBD Daniel Rios, Erik R. Sampson, Jyothsna Visweswaraiah, Patrick Halvey,Bridget Larkin, Michael J Rowe, Rajeev K. Tyagi, Jing Li, Justin Jacobse, Margret Allaman, Keith T. Wilson, Jeremy A. Goettel, Nathan Higginson-Scott, Joanne L. Viney, Kevin L. Otipoby
June 2019 Federation of Clinical Immunology Societies Annual Meeting; Boston, MA Localizing Immunomodulators to Mucosal Tissues Erik Sampson, Jyothsna Visweswaraiah, Danny Rios, Lindsay Edwards, Purvi Mande, Susmita Borthakur, Bridget Larkin, Tim Kiprono, Michael Rowe, Nathan Higginson-Scott, Kevin Otipoby, Jo Viney
June 2019 Federation of Clinical Immunology Societies Annual Meeting; Boston, MA Discovery and Characterization of PD-1 Agonist Antibodies Lindsay J. Edwards, Daniel C. Rios, Salvatore Alioto, Bridget Larkin, Timothy Kiprono, Nathan Higginson-Scott, Joanne L. Viney, Kevin L. Otipoby
June 2019 Federation of Clinical Immunology Societies Annual Meeting; Boston, MA Selective Expansion of Regulatory T cells by IL-2 Muteins Erik R. Sampson, Jyothsna Visweswaraiah, Nathan Higginson-Scott, Joanne L. Viney, Kevin L. Otipoby
May 2019 Treg Directed Therapies Summit; Boston, MA Localized Immunomodulation of Regulatory T cells in the Gut Kevin Otipoby
Apr 2019 Quantitative Systems Pharmacology Summit; Cambridge, MA Localized Immunomodulation for Treating Autoimmune Disease Nathan Higginson-Scott
Jan 2019 Host and the Environment in IBD; Taos, NM Discovery and Characterization of PD-1 Agonist Antibodies Daniel C. Rios, Lindsay Edwards, Salvatore Alioto, Bridget Larkin, Timothy Kiprono, Nathan Higginson-Scott, Joanne L. Viney, Kevin L. Otipoby
Back to Top